Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessing the therapeutic effects of DPP4 Inhibitors on TGF-β2-induced Lens Opacity.

Experimental eye research·2026

Same author

Treatment persistence with acetylcholinesterase inhibitors in Alzheimer's disease: Real-world evidence from a retrospective cohort study.

Journal of Alzheimer's disease : JAD·2026

Same author

Enzymatic Disruption of the Internal Limiting Membrane Enhances Transplanted Retinal Ganglion Cell Survival.

Investigative ophthalmology & visual science·2026

Same author

Quercetin attenuates high glucose-induced VEGFA expression in ARPE-19 cells by inhibiting ROS generation, p38 MAPK phosphorylation, and NF-κB activation.

Scientific reports·2026

Same author

Investigating interspecies mitochondrial transplantation on the malignancy of melanoma cells.

Bioscience, biotechnology, and biochemistry·2026

Same author

A practical guide to two-stage sporulation of Pyricularia oryzae: introducing a filter paper method and comparison with existing methods using strains from diverse grass hosts.

Plant methods·2025

Search research articles

Related Experiment Videos

Decrease in serum valproic acid levels during treatment with ertapenem.

Fen-Fen Liao¹, Yaw-Bin Huang, Chi-Yu Chen

¹Department of Pharmacy,Kaohsiung Medical University Hospital, No. 100 Tzyou 1st Road, Kaohsiung, Taiwan. fefeli@cc.kmu.edu.tw

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists

|July 24, 2010

Summary

This study reports a potential drug interaction between valproic acid and ertapenem, leading to significantly reduced valproic acid levels in two patients. Discontinuation of ertapenem therapy resulted in the normalization of valproic acid serum concentrations.

Related Experiment Videos

Area of Science:

Pharmacology
Clinical Pharmacy
Neuroscience

Background:

Valproic acid is a widely used antiepileptic drug.
Ertapenem is a carbapenem antibiotic.
Monitoring drug levels is crucial for effective treatment and patient safety.

Observation:

Two patients receiving valproic acid experienced a significant decrease in serum valproic acid levels after the initiation of ertapenem therapy.
In both cases, valproic acid levels dropped to below detectable limits (<1 mg/L).

Findings:

The reduction in valproic acid levels coincided with ertapenem administration.
Following the discontinuation of ertapenem, serum valproic acid levels gradually increased in both patients.
No recurrence of seizures was noted despite the initial low valproic acid levels.

Implications:

This suggests a potential pharmacokinetic interaction between valproic acid and ertapenem, possibly involving altered drug metabolism or elimination.
Clinicians should consider monitoring valproic acid levels when co-administered with ertapenem.
Further research is warranted to elucidate the mechanism of this interaction and its clinical significance.